Methods of translation and/or inflammation blockade
OwnerSung-Key JANG, Woo Jae Kiminventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of translation or inflammatory response blockade by using a compound that binds to eIF4A, which is the 264th amino acid residue, a method of developing an anti-inflammation, anti-cancer or anti-viral agent by screening a compound that binds to eIF4A.
Claims13
A method of screening an anti-cancer or anti-inflammatory drug comprising the steps of:
- contacting a candidate compound to an animal or plant cell,
- measuring inhibition of translation initiated by translational initiation factor eIF4A in vivo or in vitro, and
- determining the compound as an anti-cancer or anti-inflammatory drug when the compound causes the inhibition of translation.
A method of translation inhibition by treating a compound capable of blocking translational initiation factor eIF4A and eIF4G interaction.
A method of translation inhibition by treating a compound capable of binding to cysteine 264 of translational initiation factor eIF4A to an animal or an animal cell, to inactivate eIF4A.
A method of anti-inflammation or anti-cancer by administering a compound capable of binding to cysteine 264 of translational initiation factor eIF4A to a subject suffering with inflammation or cancer.
A derivative of 15d-PGJ2 or PGA1 targeting eIF4A useful as an anti-cancer and anti-inflammation drug.
Dependencies are inferred from the claim text.